期刊文献+

血液系统恶性肿瘤化疗后不良事件发生的危险因素分析及其风险预测模型的建立 被引量:8

Risk factors of adverse events induced by chemotherapy for hematological malignancies and establishment of a clinical risk prediction model
下载PDF
导出
摘要 目的:探寻血液系统恶性肿瘤(hematological malignancies,HMs)化疗后不良事件发生的危险因素,构建其风险预测模型。方法:采用Logistic回归分析筛选危险因素、建立风险预测模型,并用H-L卡方检验、ROC曲线对模型进行检验。结果:肝功能损害、感染、凝血功能异常、化疗强度、急性白血病、肥胖症是HMs化疗后不良事件发生的独立危险因素。H-L卡方检验(χ2=13.236,P=0.067),ROC曲线下面积为0.870,95%CI(0.844,0.895),说明模型具有较好的校准度及鉴别效度;验证组验证该模型的灵敏性、特异性、阳性预测值、阴性预测值、一致率分别是72.7%、87.4%、87.3%、73.0%、80.0%。结论:多因素Logistic回归模型能够较好地预测HMs化疗后不良事件发生的风险情况。 Objective To explore the risk factors of adverse events induced by chemotherapy for hematological malignancies (HMs), and to establish a clinical risk prediction model. Methods We used univariate and multivariate logistic regression analysis to determine the independent risk factors and established a risk model. The calibration and discrimination of the model were assessed by the H-L test and the area under the ROC curve, respectively. Results Multivariate logistic regression showed that liver dysfunction, infection, coagulation abnormalities, intensity of chemotherapy, acute leukemia, and obesity were independent risk factors for HMs patients with adverse events induced by chemotherapy. The predictive model showed better discrimination (area under the ROC curve = 0.870, 95%CI 0.844 to 0.895)and calibration (H-L statistic X2 = 13.236, P = 0.067). The sensitivity, specificity, positive predictive value, negative predictive value, and consistency rate in the prediction model group were 72.7%, 87.4%, 87.3%, 73.0%, and 80.0%, respectively. Conclusion Risk prediction model is accurate and sufficient to estimate the adverse events induced by chemotherapy for hematological malignancies.
出处 《实用医学杂志》 CAS 北大核心 2013年第7期1073-1075,共3页 The Journal of Practical Medicine
基金 国家自然科学基金项目(编号:81202358) 江苏省自然科学基金项目(编号:BK2008236) 镇江市社会发展项目(编号:SH2010030 SH2011021)
关键词 血液肿瘤 化疗不良事件 LOGISTIC模型 Hematologic neoplasms Adverse events induced by chemotherapy Logistic risk prediction model
  • 相关文献

参考文献10

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775. 被引量:2785
  • 2Chen C Y, Sheng W H, Cheng A, et al. Clinical characteristicsand outcomes .of Mycobacterium tuberculosis disease in adult patients with l:matological malignancies [J]. BMC Infect Dis, 2011, 11:324. 被引量:1
  • 3National Cancer Institute. Common Terminology Criteria Adverse Events Version 3.0(CTCAE v3.0)[S]. 2006. 被引量:1
  • 4Sorror M L, Maris M B, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT [J]. Blood, 2005, 106(8) : 2912-2919. 被引量:1
  • 5吴菲,林国桢,张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤,2012,21(2):81-85. 被引量:375
  • 6Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy [J]. EurJ Haematol,2005,74 (2): 158-165. 被引量:1
  • 7Mahale P, Kontoyiannis D P, Chemaly R F, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients [J ]. J Hepatol, 2012,57 (6) : 1177- 1185. 被引量:1
  • 8Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM -2004 study [ J ]. Haematologica, 2006,91 (8) : 1068 - 1075. 被引量:1
  • 9Hahn-Ast C, Glasmacher A, Miickter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 [J]. J Antimierob Chemother, 2010; 65(4): 761-768. 被引量:1
  • 10曲双,陈碧云,廖丽昇.伊曲康唑治疗血液病合并侵袭性真菌感染的临床分析[J].实用医学杂志,2010,26(20):3789-3790. 被引量:10

二级参考文献39

共引文献3167

同被引文献65

  • 1Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly pa- tients with diffuse large-B-cell lymphomaZoom[J]. N En- gl J Med, 2002,346 (4) : 235-242. 被引量:1
  • 2Habermann TM,Weller EA,Morrison VA,et al. Ritux-imab-CHOP versus CHOP alone or with maintenance rit- uximab in older patients with diffuse large B-cell lym- phoma [ J ]. J Clin Oncol, 2006,24 (19) : 3121-3127. 被引量:1
  • 3Vaidya R,Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era[J]. Ann Oncol, 2014,25 (11) : 2124-2133. 被引量:1
  • 4Wilder RB,Rodriguez MA, Medeiros LJ, et al. Interna- tional prognostic index-based outcomes for diffuse large B -cell lymphomas [ J ]. Cancer, 2002,94 (12) : 3083 -3088. 被引量:1
  • 5McKelvey EM,Gottlieb JA,Wilson HE,et al. Hydroxyl- daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma[J]. Cancer, 1976,38(4) : 1484-1493. 被引量:1
  • 6Fisher RI,Gaynor ER,Dahlberg S,et al. A phase 111 com- parison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non- Hodgkin's lymphoma:results of SWOG-8516 (Intergroup 0067),the National High-Priority Lymphoma Study [J]. Ann Oncol, 1994,5(Suppl 2) :91-95. 被引量:1
  • 7Abdelhamid T,Samra M,Ramadan H,et al. Clinical prog- nostic factors of diffuse large B cell non-Hodgkin lym- phoma:a retrospective study[J]. J Egypt Natl Canc Inst, 2011,23(1):17-24. 被引量:1
  • 8Rajkumar SV,Jacobus S,Callander NS,et al. Eastern Co- operative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexam- ethasone as initial therapy for newly diagnosed muhiple myeloma:an open-label randomised controlled trial [J]. Lancet Oncol, 2010,11 ( 1 ) : 29-37. 被引量:1
  • 9Pfreundschuh M,Zeynalova S, Poeschel V, et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense ritux- imab:Results of the DENSE-R-CHOP-14 trial of the Ger- man High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [J]. J Clin Oncol,2008,26(15S):8508. 被引量:1
  • 10Rajkumar SV,Jacobus S,Callander NS,et al. Eastern Co- operative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexam- ethasone as initial therapy for newly diagnosed muhiple myeloma:an open-label randomised controlled trial [J]. Lancet Oncol, 2010,11 ( 1 ) : 29-37 Pfreundschuh M,Zeynalova S,Poeschel V,et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense ritux- imab:Results of the DENSE-R-CHOP-14 trial of the Ger- man High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [J]. J Clin Oncol, 2008,26(15S) :8508. 被引量:1

引证文献8

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部